Llusern Scientific

Executive Summary

Llusern Scientific is a UK-based diagnostics company developing Lodestar DX, a point-of-care molecular testing platform for urinary tract infections (UTIs). UTIs are a common clinical challenge, often treated empirically leading to antibiotic misuse and resistance. Lodestar DX aims to provide rapid, accurate pathogen identification and antimicrobial susceptibility results within a clinic visit, enabling targeted therapy. The platform could significantly improve patient outcomes, reduce unnecessary antibiotic use, and streamline healthcare workflows. Founded in 2018 and based in London, the company is privately held and early-stage, with no disclosed funding or revenue. The product addresses a large addressable market—UTIs account for millions of visits annually—and aligns with global antimicrobial stewardship goals. However, commercialization and regulatory pathways remain unvalidated, and competition from established diagnostics firms is intense.

Upcoming Catalysts (preview)

• Q2 2026CE marking or UKCA certification for Lodestar DX40% success
• Q4 2026Strategic partnership or distribution agreement for UK/NHS rollout30% success
• H1 2027Series A funding round to support manufacturing and clinical studies20% success